Legal Experts: HHS Policy Change Strips FDA Of Oversight For All LDTs

Last week’s policy statement from HHS is “a broader directive wrapped in a COVID sandwich,” one attorney says

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.